Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
about
Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.How I treat common variable immune deficiency.Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencySafety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency.Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects.A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease
P2860
Q33391987-274AA3C1-2A28-4CF2-9308-4538E91031A7Q33396204-1B9BED3F-625A-475F-85FE-8BCBDBD4C867Q33997226-1C27D9AA-6348-4AA9-8F7E-47B7212FA4E3Q34196146-FD8CFEE0-2B33-4631-B862-5677EADCA1A4Q35566525-87053159-E57D-4A47-B88C-B8B562E124F7Q36074636-22BBE082-DA15-4E62-BCDC-8973F12BFAF1Q36196688-C1F8FC08-C90B-45D3-AB4D-060EBC01B105Q36688462-C8203C08-4539-4D4E-A520-9B664E304CA7Q37561680-201008AC-7CCD-4907-A48A-897C5374A1BCQ38042583-864E51A1-0736-4381-B454-68140F3B70E7Q38111424-560A8E4C-A201-41E1-8E00-9B5E97E2EE9BQ38188031-9EADFA76-28DC-468D-A450-DB9C2375398BQ40045651-3DC79079-7BE2-4261-A6C5-6ABFF8FBCAC4Q40179168-4263D833-13FC-4690-959E-5094D32606C4Q40343724-BBF7F93A-FC62-4AD5-A8F1-3E82F174B659Q40356366-FD688666-E1DB-4284-9F1F-8B70F33CB8E3Q40639960-0DC50C42-1505-4796-BDAB-878440F0138DQ42694622-BC75D0FF-060C-4578-9F5E-40A35B3ACBC4Q57024630-3FC1C9E9-7223-4B1F-B40B-FD3530E40485
P2860
Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@en
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@nl
type
label
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@en
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@nl
prefLabel
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@en
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@nl
P2093
P1476
Octagam 5%, an intravenous IgG ...... ary immunodeficiency diseases.
@en
P2093
Hans D Ochs
Octagam Study Group
Paul J Pinciaro
P304
P356
10.1023/B:JOCI.0000025453.23817.3F
P577
2004-05-01T00:00:00Z
P6179
1035719758